Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 161-168

  Bergey, Gregory K ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Evidence based; Idiopathic generalized epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CLOBAZAM; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABSENCE; BLOOD TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESEARCH; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MYOCLONUS SEIZURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT PLANNING; CLASSIFICATION; ORGANIZATION AND MANAGEMENT; STATISTICS; SYNDROME; UNITED STATES;

ANTICONVULSANTS; CLINICAL TRIALS; DRUG APPROVAL; EPILEPSY, GENERALIZED; HUMANS; PRACTICE GUIDELINES; SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 32944469484     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00328.x     Document Type: Review

References (60)

1. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64(6):961-5.
2. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64(6):949-54.
3. Vajda FJ, O'Brien TJ, Hitchcock A et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004;11(8):854-8.
4. Panayiotopoulos CP. Idiopathic generalized epilepsies. In: Panayiotopoulos CP, ed. The Epilepsies: Seizures, Syndromes, and Management. Oxford: Bladon Medical Publishing, 2005: 271-348.
5. Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess 2001;5(16):1-69.
6. French JA, Schachter S.Aworkshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(suppl 10):3-27.
7. Hitiris N, Brodie MJ. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia 2005;46(suppl 9):149-53.
8. Sato S, White BG, Penry JK, Dreifuss FE, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982;32(2):157-63.
9. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia 2005;46(suppl 9):133-9.
10. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38(4):408-14.
11. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11(6):470-5.
12. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41(4):479-81.
13. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(suppl 6):13-18.
14. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004;45(suppl 6):19-27.
15. Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8(5):314-7.
16. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1252-60.
17. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261-73.
18. Excellence NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. 2004. Available at www.nice.org.uk.
19. Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia 1987;28(5):495-506.
20. Schmidt D. Clobazam for treatment of intractable epilepsy: a critical assessment. Epilepsia 1994;35(suppl 5):S92-S95.
21. Remy C. Clobazam in the treatment of epilepsy: A review of the literature. Epilepsia 1994;35(suppl 5):S88-S91.
22. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 1991;32(3):407-16.
23. Excellence NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. www.nice.org.uk/CG02NICEguidelines 2004.
24. Bourgeois BF. Felbamate in the treatment of partial-onset seizures. Epilepsia 1994;35(suppl 5):S58-S61.
25. Jensen PK. Felbamate in the treatment of Lennox-Gastaut syndrome. Epilepsia 1994;35(suppl 5):S54-S57.
26. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40(7):973-9.
27. Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 2003;44(suppl 7):44-50.
28. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39(12):1329-33.
29. Coppola G, Licciardi F, Sciscio N, et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004;26(1):26-29.
30. Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004;45(9):1049-53.
31. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39(5):495-501.
32. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.NEngl JMed 1997;337(25):1807-12.
33. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5(2):149-51.
34. Morris GL, Hammer AE, Kustra RP, et al. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004;5(4):509-12.
35. Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60(8):1100-5.
36. Guerrini R, Belmonte A, Parmeggiani L, et al. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21(6):420-4.
37. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55(11):1758.
38. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56(10):1424-5.
39. Welty TE, Kuzniecky RI, Faught E. Newer antiepileptic drug outcomes in juvenile myoclonic epilepsy patients. Epilepsia 2004;45(suppl 7):145-6.
40. Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004;62(4):640-3.
41. Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed Levetiracetam in an epilepsy clinic - a one year follow up study. Seizure 2003;12(3):136-40.
42. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003;12(8):617-20.
43. Ferrie CD, Robinson RO, Knott C, et al. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995;91(3):200-2.
44. Tata MR, Natale E, Fierro B, Ornella D. Levetiracetam in the treatment of primary generalized seizures. Epilepsia 2004;45(suppl 7):315.
45. Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol 2004;61:1604-7.
46. Verdru P, Wajgt A, Schiemann Delgado J, et al. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures. Epilepsia 2005;46(suppl 6):56-7.
47. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52(7):1330-7.
48. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(suppl 1):S7-S13.
49. Ben-Menachem E, YTC-E Study Group. A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of nonfocal origin. Epilepsia 1997;30(suppl 3):60.
50. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2004;107:165-75.
51. Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002;11(6):406-10.
52. Levisohn P, Holland KD, Hulihan JF, et al. Topiramate vs valproate in patients with juvenile myoclonic epilepsy. Epilepsia 2003;44(suppl 9):267.
53. Yanagaki S, Oguni H, Yoshii K, et al. Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. Brain Dev 2005;27(4):286-90.
54. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29(2):109-14.
55. Reigle SC, Gaillard WD, Pearl PL, et al. Progressive myoclonic epilepsy (PME): response of seizures to zonisamide. Epilepsia 2001;42(suppl 7):54.
56. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies-our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16(1):79-85.
57. Andriola MRMMA, Vitale SJ, Firas B, Guido M. Zonisamide as adjunctive and monotherapy in absence epilepsy. Epilepsia 2002;43(suppl 7):190.
58. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;64(1-2):31-34.
59. Biton V, Bebin ME. Multicenter, open-label assessment of the efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2002;43(suppl 7):190.
60. Welty TE, Martin JE, Faught E, et al. Comparisons of outcomes in patients with juvenile myoclonic epilepsy treated with lamotrigine, topiramate, zonisamide, or levetiracetam. Epilepsia 2002;43(suppl 7):239.